Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Regulatory News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.53
Bid: 1.53
Ask: 1.60
Change: -0.002 (-0.13%)
Spread: 0.07 (4.575%)
Open: 1.53
High: 1.53
Low: 1.53
Prev. Close: 1.567
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

27 May 2021 11:15

RNS Number : 0553A
Hemogenyx Pharmaceuticals PLC
27 May 2021
 

27 May 2021

 

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

 

TR-1 Standard form for notification of major holdings

 

Issuer Details

ISIN

GB00BYX3WZ24

Issuer Name

HEMOGENYX PHARMACEUTICALS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An event changing the breakdown of voting

3. Details of person subject to the notification obligation

Name

Alexis Sandler

City of registered office (if applicable)

New York

Country of registered office (if applicable)

United States of America

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

26-May-2021

6. Date on which Issuer notified

26-May-2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

7.660000

0.000000

7.660000

75090685

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BYX3WZ24

75090685

7.660000

Sub Total 8.A

75090685

7.660000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

 

13. Place Of Completion

London

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUBARRARUVUAR
Date   Source Headline
12th Jun 20197:00 amRNSCDX Effective as Conditioning Therapeutic in vivo
5th Jun 20198:15 amRNSCDX Antibody is Effective against AML in vivo
30th May 20194:40 pmRNSSecond Price Monitoring Extn
30th May 20194:35 pmRNSPrice Monitoring Extension
30th May 20197:00 amRNSCDX Antibody is Effective against ALL in vitro
28th May 20197:00 amRNSPosting of Annual Report and Notice of AGM
15th May 20197:00 amRNSVariation of Terms of Warrant Instrument
1st May 20197:00 amRNSDirector/PDMR Shareholding
29th Apr 20193:10 pmRNSFinal Results for the Year Ended 31 December 2018
30th Jan 20197:00 amRNSPresentation at Cancer Immunotherapy Conference
7th Jan 20197:00 amRNSOperations Update
20th Dec 20187:00 amRNSDirectorate Change
5th Nov 20187:00 amRNSDirectorate Change & Appointment
22nd Oct 20187:00 amRNSOrgenesis collaboration for Hu-PHEC development
19th Oct 20187:00 amRNSCollaboration, License and Investment by Orgenesis
15th Oct 20187:00 amRNSCollaboration with Johnson & Johnson Innovation
28th Sep 20189:30 amRNSHalf-year Report
28th Sep 20187:00 amRNSChange of Adviser
3rd Sep 20187:00 amRNSHemogenyx to present at Oxford conference
27th Jun 201811:39 amRNSResult of AGM
8th Jun 20187:00 amRNSInvestor presentation
5th Jun 20186:05 pmRNSPosting of Annual Report & Notice of AGM
14th May 20187:00 amRNSDevelopment Agreement
8th May 20187:00 amRNSResearch Collaboration with Rockefeller University
30th Apr 20184:23 pmRNSFinal Results
11th Apr 20185:15 pmRNSDirector/PDMR Shareholding
3rd Apr 20187:00 amRNSDirectorate Change
14th Mar 201811:05 amRNSSecond Price Monitoring Extn
14th Mar 201811:00 amRNSPrice Monitoring Extension
13th Mar 20187:00 amRNSCollaboration with major US biotechnology company
6th Mar 20187:00 amRNSAdvisory Board Appointment
1st Mar 20187:00 amRNSAlign Research Initiation of Coverage
27th Feb 20184:40 pmRNSSecond Price Monitoring Extn
27th Feb 20184:35 pmRNSPrice Monitoring Extension
26th Feb 20182:17 pmRNSStmnt re Share Price Movement
12th Feb 20187:00 amRNSDirector/PDMR Shareholding
7th Feb 20187:00 amRNSDirector/PDMR Shareholding
11th Jan 20187:00 amRNSHemogenyx Welcomes N.Y. Lt. Governor to its Labs
7th Dec 201712:16 pmRNSResult of AGM
7th Dec 20177:00 amRNSAGM Statement
20th Nov 20177:00 amRNSUniversity of Oxford Collaboration
15th Nov 20177:00 amRNSDirectorate Change
14th Nov 20177:00 amRNSNotice of AGM
13th Nov 20174:40 pmRNSSecond Price Monitoring Extn
13th Nov 20174:35 pmRNSPrice Monitoring Extension
13th Nov 20172:05 pmRNSSecond Price Monitoring Extn
13th Nov 20172:00 pmRNSPrice Monitoring Extension
13th Nov 201711:05 amRNSSecond Price Monitoring Extn
13th Nov 201711:00 amRNSPrice Monitoring Extension
13th Nov 20179:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.